(Q37034610)

17 August 2017

1 reference

title

Development of protease inhibitors and the fight with drug-resistant HIV-1 variants (English)

1 reference

17 August 2017

0 references

Hiroaki Mitsuya

1

1 reference

17 August 2017

Kenji Maeda

series ordinal

2

1 reference

17 August 2017

Debananda Das

series ordinal

3

1 reference

17 August 2017

Arun K Ghosh

series ordinal

4

1 reference

17 August 2017

language of work or name

1 reference

1 January 2008

1 reference

17 August 2017

published in

Advances in Pharmacology

1 reference

17 August 2017

volume

56

1 reference

17 August 2017

page(s)

169-197

1 reference

TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Toxicity of antiretroviral therapy and implications for drug development

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Non-peptidic HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Flap opening in HIV-1 protease simulated by 'activated' molecular dynamics.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Strategies in the design of antiviral drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Structure and Function of Retroviral Proteases

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

New patterns of HIV-1 resistance during HAART

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Altered HIV-1 Gag protein interactions with cyclophilin A (CypA) on the acquisition of H219Q and H219P substitutions in the CypA binding loop

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

3-Tetrahydrofuran and pyran urethanes as high-affinity P2-ligands for HIV-1 protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Structure-based design of HIV-1 protease inhibitors: replacement of two amides and a 10 pi-aromatic system by a fused bis-tetrahydrofuran

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Structure based design: novel spirocyclic ethers as nonpeptidal P2-ligands for HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Structure-based design of non-peptide HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Antiviral activity of UIC-PI, a novel inhibitor of the human immunodeficiency virus type 1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Design and synthesis of novel HIV-1 protease inhibitors incorporating oxyindoles as the P2'-ligands

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Bis-tetrahydrofuran: a privileged ligand for darunavir and a new generation of hiv protease inhibitors that combat drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Decreased exposure to saquinavir in HIV-1-infected patients after long-term antiretroviral therapy including ritonavir and saquinavir

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

HIV infection in older patients in the HAART era.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug r

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Immune reconstitution in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Active-site mobility in human immunodeficiency virus, type 1, protease as demonstrated by crystal structure of A28S mutant

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

HIV-1 protease flaps spontaneously open and reclose in molecular dynamics simulations

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Progression of early steps of human immunodeficiency virus type 1 replication in the presence of an inhibitor of viral protease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Structure-based, C2 symmetric inhibitors of HIV protease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type 1 protease: relationship to drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Antiretroviral-drug resistance among patients recently infected with HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Strategies for antiviral therapy in AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Molecular targets for AIDS therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Adaptive inhibitors of the HIV-1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

How many drug targets are there?

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

How does a symmetric dimer recognize an asymmetric substrate? A substrate complex of HIV-1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Viability of a drug-resistant human immunodeficiency virus type 1 protease variant: structural insights for better antiviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Peptidomimetic inhibitors of HIV protease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Rational design of peptide-based HIV proteinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

How flexible is tipranavir in complex with the HIV-1 protease active site?

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Molecular significance of tipranavir related codon 33 protease gene mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

A long-term latent reservoir for HIV-1: discovery and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

HIV-1 dynamics in vivo: implications for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Design of HIV-1 protease inhibitors active on multidrug-resistant virus

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Amino acid insertions near Gag cleavage sites restore the otherwise compromised replication of human immunodeficiency virus type 1 variants resistant to protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

In vitro induction of human immunodeficiency virus type 1 variants resistant to 2'-beta-Fluoro-2',3'-dideoxyadenosine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Targeting proteases: successes, failures and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Tipranavir (PNU-140690): A Potent, Orally Bioavailable Nonpeptidic HIV Protease Inhibitor of the 5,6-Dihydro-4-hydroxy-2-pyrone Sulfonamide Class∇

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Overcoming HIV drug resistance through rational drug design based on molecular, biochemical, and structural profiles of HIV resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

Acquisition of multi-PI (protease inhibitor) resistance in HIV-1 in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956006-0

7 January 2021

10.1016/S1054-3589(07)56006-0

Identifiers

DOI

1 reference

17 August 2017

1 reference